News & Media

Events
Erik Penser Bank - Life Science Day

Read more
Press release
Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients...

Read more
Press release
Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Life Science Day,...

Read more
Press release
Birinapant clinical study initiated by IGM Biosciences

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2021

Positive MIV-818 data presented at ESMO. New positive data and renegotiated agreement for remetinostat July – September Financial summary for the...

Read more
Press release
Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Read more
Press release
Medivir Appoints Jens Lindberg as Chief Executive Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors  has appointed Jens Lindberg as CEO...

Read more
Press release
A joint patent application for MALT1 inhibitors published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a joint patent application for MALT1 inhibitors submitted together with...

Read more
Press release
Medivir to present at the ProHearings shared Capital Markets Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets...

Read more
Press release
Medivir invites to a conference call on new clinical data and further studies with MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed...

Read more
Press release
Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled “Phase 1 study of the novel prodrug...

Read more
Press release
Medivir to present at the Wainwright Annual Global Investment Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright...

Read more